IN2012DN03418A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03418A
IN2012DN03418A IN3418DEN2012A IN2012DN03418A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A IN 3418DEN2012 A IN3418DEN2012 A IN 3418DEN2012A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A
Authority
IN
India
Prior art keywords
induces
immunogenic composition
whole
response
primarily antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Richard Malley
Porter Anderson
Yingjie Lu
George A Robertson
Mark Alderson
Jean-Francois Lucien Maisonneuve
Andrea Maria Tate
Oliverira Dias Waldely De
Goncalves Viviane Maimoni
Original Assignee
Childrens Medical Center
Path Vaccine Solutions
Fundacao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Path Vaccine Solutions, Fundacao Butantan filed Critical Childrens Medical Center
Publication of IN2012DN03418A publication Critical patent/IN2012DN03418A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3418DEN2012 2009-10-09 2010-10-12 IN2012DN03418A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25034809P 2009-10-09 2009-10-09
US38042910P 2010-09-07 2010-09-07
PCT/US2010/052298 WO2011044576A2 (en) 2009-10-09 2010-10-12 Selectively disrupted whole-cell vaccine

Publications (1)

Publication Number Publication Date
IN2012DN03418A true IN2012DN03418A (cg-RX-API-DMAC7.html) 2015-10-23

Family

ID=43857436

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3418DEN2012 IN2012DN03418A (cg-RX-API-DMAC7.html) 2009-10-09 2010-10-12

Country Status (5)

Country Link
US (1) US9827299B2 (cg-RX-API-DMAC7.html)
EP (1) EP2485764A4 (cg-RX-API-DMAC7.html)
CN (1) CN102648003B (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03418A (cg-RX-API-DMAC7.html)
WO (1) WO2011044576A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
BR112013027845A2 (pt) * 2011-05-18 2017-01-03 Ajinomoto Kk Imunoestimulante, ração, método para produzir um imunoestimulante, e, método para imunoestimulação
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
WO2021252954A2 (en) * 2020-06-12 2021-12-16 Schossau Tom M Inactivation of genome enveloped within coronavirus spherical or pleomorphic particles or shells to form a vaccine
CA3231684A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
CN117756959B (zh) * 2024-02-22 2024-05-14 北京民海生物科技有限公司 一种肺炎链球菌荚膜多糖的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6612233A (cg-RX-API-DMAC7.html) * 1966-08-30 1968-03-01
NL7012832A (cg-RX-API-DMAC7.html) * 1970-08-29 1972-03-02
US3852420A (en) * 1971-01-20 1974-12-03 Richardson Merrell Inc Equine strangles vaccine and method of preparing and using the same
FR2174745A1 (en) * 1972-03-09 1973-10-19 Inst Elevage Med Vet Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4675176A (en) 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
DE3715840A1 (de) * 1987-05-12 1988-12-01 Boehringer Mannheim Gmbh Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung
GB8906795D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
WO1991004742A1 (en) * 1989-10-06 1991-04-18 Szabo Janos Pharmaceutical composition for the treatment of skin diseases, especially pyogenous and atopic dermatitis and process for the preparation thereof
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
ES2186694T3 (es) 1990-06-07 2003-05-16 Bayer Ag Vacuna bacteriana para el tratamiento de necrosis hepatica causada por f. necrophorum.
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
WO1993021951A1 (en) 1992-04-27 1993-11-11 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
AUPN175495A0 (en) * 1995-03-14 1995-04-13 University Of New England, The Method and composition for the prevention of the over production of acid
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
DE69739981D1 (de) * 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5958414A (en) 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
WO1999020303A1 (en) 1997-10-20 1999-04-29 Bayer Corporation Neospora vaccines
US7172762B1 (en) 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
AU782508B2 (en) 1999-11-08 2005-08-04 Biomune Vaccines for mycoplasma bovis and methods of use
DE10003241A1 (de) * 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6378677B1 (en) * 2000-10-03 2002-04-30 Honda Giken Kogyo Kabushiki Kaisha Power transmission device having electromagnetic clutch
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
DE60232071D1 (de) * 2001-06-11 2009-06-04 Applied Nanosystems Bv Verfahren zur bindung von acma-typ protein anker fusionen an mikroorganismen zellwandmaterialien
NZ530780A (en) 2001-07-11 2005-06-24 Werner Lubitz Nucleic acid free ghost preparations
ES2584305T3 (es) * 2001-10-15 2016-09-27 Engeneic Molecular Delivery Pty Ltd. Minicélulas intactas como vectores para transferencia de ADN y terapia génica in vitro e in vivo
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
WO2004096247A1 (ja) * 2003-04-28 2004-11-11 Sekisui Chemical Co., Ltd. サイトカイン誘導用具及びサイトカイン誘導方法
US7204993B2 (en) * 2004-03-18 2007-04-17 The United States Of America As Represented By The Secretary Of Agriculture Streptococcus agalactiae vaccine
US7211428B1 (en) * 2004-05-18 2007-05-01 Council Of Scientific And Industrial Research Strain of Bacillus as a bioinoculant
US7291276B1 (en) * 2004-06-21 2007-11-06 Winston Company, Inc. Controlled production and release of oxygen activated biocide into holding tanks for RV's, boats and the like
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
WO2006017895A1 (en) 2004-08-17 2006-02-23 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
KR20070089231A (ko) * 2004-12-14 2007-08-30 알크-아벨로 에이/에스 이종 단백질성 화합물을 제시하는 박테리아 세포를포함하는 약제학적 조성물
US20090214596A1 (en) * 2005-04-01 2009-08-27 Riken Nasal Vaccine
EP2371843B1 (en) * 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
EP1746103A1 (en) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunctional protein anchors
WO2008039171A2 (en) * 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
BRPI0621760A2 (pt) * 2006-07-10 2011-12-20 Univ Arizona State molécula de ácido nucléico recombinante que não ocorre naturalmente, célula recombinante, composição imunogênica, anticorpo, método para detectar a presença de proteìna pilus de campylobacter e método para detectar um anticorpo que se liga especificamente a uma proteìna pilus de campylobacter jejuni
JP5249326B2 (ja) * 2007-07-23 2013-07-31 ワクチン リサーチ インターナショナル ピーエルシー 不活化ブドウ球菌全細胞ワクチン
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
TW201043242A (en) * 2009-03-26 2010-12-16 Intervet Int Bv Vaccine for protection against Streptococcus suis bacteria of various serotypes
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
US8668911B2 (en) * 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
SI2475384T1 (sl) * 2009-09-10 2016-12-30 Merial, Inc. Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin
KR20120115976A (ko) * 2009-12-07 2012-10-19 시냅틱 리서치, 엘엘씨 프로테아제 활성 저해제의 동정 방법 및 프로테아제 활성의 존재 분석 방법

Also Published As

Publication number Publication date
WO2011044576A2 (en) 2011-04-14
EP2485764A2 (en) 2012-08-15
CN102648003B (zh) 2016-01-13
WO2011044576A3 (en) 2011-08-18
EP2485764A4 (en) 2014-01-29
US9827299B2 (en) 2017-11-28
US20120251577A1 (en) 2012-10-04
CN102648003A (zh) 2012-08-22

Similar Documents

Publication Publication Date Title
IL273607A (en) Humanized antibodies against liv-1, preparations containing them and their uses
IN2012DN03418A (cg-RX-API-DMAC7.html)
MX362039B (es) Anticuerpos anti-il-23.
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
PH12013501942A1 (en) Antibody-drug conjugates
WO2010145792A8 (en) Bispecific antigen binding proteins
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EP3038644A4 (en) Site-specific antibody conjugation methods and compositions
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
WO2009135181A3 (en) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MX2010006395A (es) Formulacion de anticuerpos.
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
WO2011063350A3 (en) Methods and compositions for producing squalene using yeast
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
MY170720A (en) Antibody formulations
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
IL219801A (en) Anti-a4 antibody. 4c isolates, vectors encoded by them, methods of preparation, preparations containing them and their use
MX2011011512A (es) Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
MX2013012184A (es) Composiciones formadoras de gel in situ.
MX354924B (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2012121746A3 (en) Imaging beta cell mass